Dushyant Singh Dahiya, Ganesh Kumar, Syeda Parsa, Manesh Kumar Gangwani, Hassam Ali, Amir Humza Sohail, Saqr Alsakarneh, Umar Hayat, Sheza Malik, Yash R Shah, Bhanu Siva Mohan Pinnam, Sahib Singh, Islam Mohamed, Adishwar Rao, Saurabh Chandan, Mohammad Al-Haddad
Worldwide, a majority of routine endoscopic procedures are performed under some form of sedation to maximize patient comfort. Propofol, benzodiazepines and opioids continue to be widely used. However, in recent years, Remimazolam is gaining immense popularity for procedural sedation in gastrointestinal (GI) endoscopy. It is an ultra-short-acting benzodiazepine sedative which was approved by the Food and Drug Administration in July 2020 for use in procedural sedation. Remimazolam has shown a favorable pharmacokinetic and pharmacodynamic profile in terms of its non-specific metabolism by tissue esterase, volume of distribution, total body clearance, and negligible drug-drug interactions...
July 16, 2024: World Journal of Gastrointestinal Endoscopy